{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:08:26Z","timestamp":1792624106823,"version":"4.5.0"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY16352"],"award-info":[{"award-number":["EY16352"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["EY21247"],"award-info":[{"award-number":["EY21247"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010390","name":"Saint Louis University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010390","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Herpes simplex virus (HSV) is an alpha herpes virus, with two subtypes: HSV-1 and HSV-2. HSV is one of the most prevalent sexually transmitted infections. It is the cause of severe neonatal infections and a leading cause of infectious blindness in the Western world. As of 2016, 13.2% of the global population ages 15\u201349 were existing with HSV-2 infection and 66.6% with HSV-1. This high prevalence of disease and the fact that resistance to current therapies is on the rise makes it imperative to develop and discover new methods of HSV prevention and management. Among the arsenal of therapies\/treatments for this virus has been the development of a prophylactic or therapeutic vaccine to prevent the complications of HSV reactivation. Our current understanding of the immune responses involved in latency and reactivation provides a unique challenge to the development of vaccines. There are no approved vaccines currently available for either prophylaxis or therapy. However, there are various promising candidates in the pre-clinical and clinical phases of study. Vaccines are being developed with two broad focuses: preventative and therapeutic, some with a dual use as both immunotherapeutic and prophylactic. Within this article, we will review the current guidelines for the treatment of herpes simplex infections, our understanding of the immunological pathways involved, and novel vaccine candidates in development.<\/jats:p>","DOI":"10.3389\/fmicb.2021.798927","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T04:00:41Z","timestamp":1638849641000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":81,"title":["Developments in Vaccination for Herpes Simplex Virus"],"prefix":"10.3389","volume":"12","author":[{"given":"Rohini","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"ref1","volume-title":"Molecular Biology of the Cell.","author":"Alberts","year":"2002"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/infdis\/jiu177","article-title":"Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine","volume":"210","author":"Awasthi","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"eaaw7083","DOI":"10.1126\/sciimmunol.aaw7083","article-title":"Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes","volume":"4","author":"Awasthi","year":"2019","journal-title":"Sci. Immunol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e1006141","DOI":"10.1371\/journal.ppat.1006141","article-title":"An HSV-2 trivalent vaccine is immunogenic in rhesus macaques and highly efficacious in Guinea pigs","volume":"13","author":"Awasthi","year":"2017","journal-title":"PLoS Pathog."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"10472","DOI":"10.1128\/JVI.00849-11","article-title":"Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in Guinea pigs compared to immunization with gD alone","volume":"85","author":"Awasthi","year":"2011","journal-title":"J. Virol."},{"key":"ref6","first-page":"2140","article-title":"Antiviral therapy (Non-HIV)","volume-title":"Goldman-Cecil Medicine.","author":"Beigel","year":"2020"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/archneur.65.5.596","article-title":"Neurological complications of herpes simplex virus type 2 infection","volume":"65","author":"Berger","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e0121518","DOI":"10.1371\/journal.pone.0121518","article-title":"Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and Guinea pigs","volume":"10","author":"Bernard","year":"2015","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41541-020-00254-8","article-title":"The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a Guinea pig model","volume":"5","author":"Bernstein","year":"2020","journal-title":"NPJ Vacc."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1016\/j.vaccine.2019.05.009","article-title":"Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/infdis\/jix004","article-title":"Therapeutic vaccine for genital herpes simplex Virus-2 infection: findings From a randomized trial","volume":"215","author":"Bernstein","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2016.01.013","article-title":"HSV antivirals - current and future treatment options","volume":"18","author":"Birkmann","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref14","year":"2019"},{"key":"ref15","article-title":"Human herpesviruses","volume-title":"Dermatology.","author":"Bolognia","year":"2018"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41541-020-0184-7","article-title":"Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity","volume":"5","author":"Burn Aschner","year":"2020","journal-title":"NPJ vaccines"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/infdis\/jix628","article-title":"A herpes simplex virus (HSV)-2 single-cycle candidate vaccine deleted in glycoprotein D protects male mice From lethal skin challenge With clinical isolates of HSV-1 and HSV-2","volume":"217","author":"Burn","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1684\/vir.2020.0864","article-title":"R\u00e9sistance des virus herpes simplex aux antiviraux [Herpes simplex virus resistance to antivirals]","volume":"24","author":"Burrel","year":"2020","journal-title":"Virologie"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e0226320","DOI":"10.1371\/journal.pone.0226320","article-title":"Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I\/IIa trial","volume":"14","author":"Chandra","year":"2019","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1128\/JVI.00302-12","article-title":"A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections","volume":"86","author":"Chiuppesi","year":"2012","journal-title":"J. Virol."},{"key":"ref21","year":"2020"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijpharm.2012.06.042","article-title":"Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes","volume":"440","author":"Cortesi","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511545313.003","article-title":"Comparative Analysis of the Genomes","volume-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis.","author":"Davison","year":"2007"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-9814-2_1","article-title":"Tour de herpes: cycling Through the life and biology of HSV-1","volume":"2060","author":"Denes","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1128\/JVI.72.3.2010-2021.1998","article-title":"The genome sequence of herpes simplex virus type 2","volume":"72","author":"Dolan","year":"1998","journal-title":"J. Virol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/infdis\/jiz225","article-title":"A randomized, double-blinded, placebo-controlled, phase 1 study of a replication-defective herpes simplex virus (HSV) type 2 vaccine, HSV529, in adults With or Without HSV infection","volume":"220","author":"Dropulic","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e76407","DOI":"10.1371\/journal.pone.0076407","article-title":"A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice","volume":"8","author":"Dutton","year":"2013","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1080\/21645515.2020.1749509","article-title":"Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects Guinea pigs against HSV-1 genital infection","volume":"16","author":"Egan","year":"2020","journal-title":"Hum. Vacc. Immuno."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/ni.1720","article-title":"Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection","volume":"10","author":"English","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1016\/j.vaccine.2016.09.001","article-title":"Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1\/2a trial","volume":"34","author":"Flechtner","year":"2016","journal-title":"Vaccine"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"11137","DOI":"10.1128\/jvi.74.23.11137-11144.2000","article-title":"Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain","volume":"74","author":"Geiss","year":"2000","journal-title":"J. Virol."},{"key":"ref32","year":"2018"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1086\/424519","article-title":"Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract","volume":"190","author":"Gupta","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/jmv.1890140303","article-title":"Specific IgG and IgA antibodies to herpes simplex virus (HSV)-induced surface antigen in patients with HSV infections and in healthy adults","volume":"14","author":"Hadar","year":"1984","journal-title":"J. Med. Virol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e17748","DOI":"10.1371\/journal.pone.0017748","article-title":"A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine","volume":"6","author":"Halford","year":"2011","journal-title":"PLoS One"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e12251","DOI":"10.1371\/journal.pone.0012251","article-title":"Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine","volume":"5","author":"Halford","year":"2010","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2340\/00015555-0806","article-title":"Prevention of ulcerative lesions by episodic treatment of recurrent herpes labialis: A literature review","volume":"90","author":"Harmenberg","year":"2010","journal-title":"Acta Derm. Venereol."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","article-title":"Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine","volume":"59","author":"Heineman","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.vaccine.2018.11.076","article-title":"A trivalent gC2\/gD2\/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection","volume":"37","author":"Hook","year":"2019","journal-title":"Vaccine"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1128\/JVI.80.8.4038-4046.2006","article-title":"Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody","volume":"80","author":"Hook","year":"2006","journal-title":"J. Virol."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1016\/j.vaccine.2013.06.081","article-title":"Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial","volume":"31","author":"Abu-Elyazeed","year":"2013","journal-title":"Vaccine"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.vaccine.2010.12.031","article-title":"An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice","volume":"29","author":"Hu","year":"2011","journal-title":"Vaccine"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes simplex virus: global infection prevalence and incidence estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull. World Health Organ."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e00993-19","DOI":"10.1128\/MRA.00993-19","article-title":"Complete genome sequence of herpes simplex virus 1 strain McKrae","volume":"8","author":"Jiao","year":"2019","journal-title":"Microbiol. Res. Announce."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1016\/j.vaccine.2015.12.076","article-title":"Status of vaccine research and development of vaccines for herpes simplex virus","volume":"34","author":"Johnston","year":"2016","journal-title":"Vaccine"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13054-015-1046-y","article-title":"Long-term outcome of severe herpes simplex encephalitis: a population-based observational study","volume":"19","author":"Jouan","year":"2015","journal-title":"Crit. Care"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: From whole organisms to rationally designed protein assemblies","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1086\/514049","article-title":"Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice","volume":"176","author":"Keadle","year":"1997","journal-title":"J. Infec. Dis."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1128\/jvi.76.8.3615-3625.2002","article-title":"Therapeutic immunization with a virion host shutoff (vhs) defective, replication-incompetent HSV-1 strain limits recurrent herpetic ocular infection","volume":"76","author":"Keadle","year":"2002","journal-title":"J. Virol."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"44084","DOI":"10.1038\/srep44084","article-title":"Worldwide circulation of HSV-2\u00d7HSV-1 recombinant strains","volume":"7","author":"Koelle","year":"2017","journal-title":"Sci. Rep."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"12164","DOI":"10.1128\/JVI.01676-09","article-title":"Interaction of ICP34.5 with Beclin 1 modulates herpes simplex virus type 1 pathogenesis through control of CD4+ T-cell responses","volume":"83","author":"Leib","year":"2009","journal-title":"J. Virol."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"478","DOI":"10.2174\/156652321306140103224550","article-title":"Biosafety of gene therapy vectors derived from herpes simplex virus type 1","volume":"13","author":"Lim","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1179\/016164113X13703372991516","article-title":"HSV-1 activates NF-kappaB in mouse astrocytes and increases TNF-alpha and IL-6 expression via toll-like receptor 3","volume":"35","author":"Liu","year":"2013","journal-title":"Neurol. Res."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"718753","DOI":"10.3389\/fbioe.2021.718753","article-title":"Development and delivery systems of mRNA vaccines","volume":"9","author":"Liu","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1084\/jem.20030162","article-title":"Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells","volume":"198","author":"Lund","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"617578","DOI":"10.3389\/fcimb.2020.617578","article-title":"Herpes simplex virus cell entry mechanisms: An update","volume":"10","author":"Madavaraju","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.chom.2017.12.014","article-title":"Herpes simplex virus 1 VP22 inhibits AIM2-dependent Inflammasome activation to enable efficient viral replication","volume":"23","author":"Maruzuru","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"8530","DOI":"10.1016\/j.vaccine.2011.07.011","article-title":"A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy","volume":"29","author":"Mo","year":"2011","journal-title":"Vaccine"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.vaccine.2015.10.137","article-title":"A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and Guinea pigs","volume":"34","author":"Odegard","year":"2016","journal-title":"Vaccine"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"e06054","DOI":"10.7554\/eLife.06054","article-title":"Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease","volume":"4","author":"Petro","year":"2015","journal-title":"Elife"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e88529","DOI":"10.1172\/jci.insight.88529","article-title":"HSV-2 \u0394gD elicits Fc\u03b3R-effector antibodies that protect against clinical isolates","volume":"1","author":"Petro","year":"2016","journal-title":"JCI Insight"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/QCO.0000000000000288","article-title":"Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management","volume":"29","author":"Piret","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1016\/j.vaccine.2005.02.028","article-title":"Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in Guinea pigs","volume":"23","author":"Prichard","year":"2005","journal-title":"Vaccine"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e1006741","DOI":"10.1371\/journal.ppat.1006741","article-title":"The pUL37 tegument protein guides alpha-herpesvirus retrograde axonal transport to promote neuroinvasion","volume":"13","author":"Richards","year":"2017","journal-title":"PLoS Pathog."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4161\/hv.29344","article-title":"Vical initiates vaccine trials against HSV-2 and CMV","volume":"10","author":"Riedmann","year":"2014","journal-title":"Hum. Vacc. Immuno."},{"key":"ref67","first-page":"938","article-title":"Role of T-lymphocytes in the pathogenesis of herpetic stromal keratitis","volume":"8","author":"Russell","year":"1984","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"18973","DOI":"10.1073\/pnas.1006614107","article-title":"Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes","volume":"107","author":"Schiffer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"14559","DOI":"10.1073\/pnas.0405924101","article-title":"Therapeutic vaccines: realities of today and hopes for tomorrow","volume":"101","author":"Sela","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1099\/vir.0.040055-0","article-title":"Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection","volume":"93","author":"Shlapobersky","year":"2012","journal-title":"J. Gen. Virol."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.1128\/JVI.02745-12","article-title":"An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs","volume":"87","author":"Skoberne","year":"2013","journal-title":"J. Virol."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.vaccine.2016.12.018","article-title":"Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 sti- mulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies","volume":"35","author":"Stanfield","year":"2017","journal-title":"Vaccine"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1016\/j.vaccine.2018.03.075","article-title":"Intramuscular vaccination of Guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses","volume":"36","author":"Stanfield","year":"2018","journal-title":"Vaccine"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"e109890","DOI":"10.1371\/journal.pone.0109890","article-title":"A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains","volume":"9","author":"Stanfield","year":"2014","journal-title":"PLoS One"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fimmu.2019.00373","article-title":"Mechanisms of immune control of mucosal HSV infection: A guide to rational vaccine design","volume":"10","author":"Truong","year":"2019","journal-title":"Front. Immunol."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/ICU.0000000000000618","article-title":"Ocular manifestations of herpes simplex virus","volume":"30","author":"Valerio","year":"2019","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"14843","DOI":"10.1128\/JVI.79.23.14843-14851.2005","article-title":"Latent infection with herpes simplex virus is associated with ongoing CD8+ T-cell stimulation by parenchymal cells within sensory ganglia","volume":"79","author":"Van Lint","year":"2005","journal-title":"J. Virol."},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/infdis\/jiy415","article-title":"Effects of different doses of GEN-003, a therapeutic vaccine for genital herpes simplex Virus-2, on viral shedding and lesions: results of a randomized placebo-controlled trial","volume":"218","author":"Van Wagoner","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1073\/pnas.0610847104","article-title":"Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia","volume":"104","author":"Verjans","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"7046","DOI":"10.1016\/j.vaccine.2012.09.057","article-title":"A Vaxfectin(R)-adjuvanted HSV- 2 plasmid DNA vaccine is effective for pro- phylactic and therapeutic use in the Guinea pig model of genital herpes","volume":"30","author":"Veselenak","year":"2012","journal-title":"Vaccine"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00430-012-0247-0","article-title":"Herpes simplex virus type 1 induces simultaneous activation of toll-like receptors 2 and 4 and expression of the endogenous ligand serum amyloid A in astrocytes","volume":"201","author":"Villalba","year":"2012","journal-title":"Med. Microbiol. Immunol."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1016\/j.vaccine.2011.09.046","article-title":"Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons","volume":"29","author":"Wald","year":"2011","journal-title":"Vaccine"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/infdis\/jiab139","article-title":"Serum and Cervicovaginal fluid antibody profiling in herpes simplex virus (HSV) Seronegative recipients of the HSV529 vaccine","volume":"224","author":"Wang","year":"2021","journal-title":"J. Inf. Dis."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1128\/JVI.71.8.6083-6093.1997","article-title":"Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry","volume":"71","author":"Whitbeck","year":"1997","journal-title":"J. Virol."},{"key":"ref85","first-page":"2189","article-title":"Chapter 350: Herpes Simplex Virus Infections","volume-title":"Goldman-Cecil Medicine.","author":"Whitley","year":"2019"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1086\/432477","article-title":"Development of herpes simplex virus disease in patients who are receiving cidofovir","volume":"41","author":"Wyles","year":"2005","journal-title":"Clin. Pub. Inf. Dis. Soc. Am."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"e2054","DOI":"10.1002\/rmv.2054","article-title":"Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development","volume":"29","author":"Xu","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"ref88","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/v13020338","article-title":"Development of genome editing approaches against herpes simplex virus infections","volume":"13","author":"Zhang","year":"2021","journal-title":"Viruses"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"e101373","DOI":"10.1371\/journal.pone.0101373","article-title":"A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in Guinea pigs","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1084\/jem.20061792","article-title":"Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation","volume":"204","author":"Zhu","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"e00099-20","DOI":"10.1128\/MMBR.00099-20","article-title":"The race between host antiviral innate immunity and the immune evasion strategies of herpes simplex virus 1","volume":"84","author":"Zhu","year":"2020","journal-title":"Microbiol Mol Biol Rev"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.798927\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T04:00:50Z","timestamp":1638849650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.798927\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":91,"alternative-id":["10.3389\/fmicb.2021.798927"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.798927","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"article-number":"798927"}}